Search results
Showing 6421 to 6435 of 9128 results
Recommendation ID NG122/1 Question What is the effectiveness and cost effectiveness of immunotherapy in people with stage IIIA-N2 non-small-cell
Recommendation ID IPG619/1 Question Research on the safety and efficacy of superior capsular augmentation for massive rotator cuff tears
Recommendation ID NG50/8 Question Acute hepatic encephalopathy:- In people with cirrhosis and an acute episode of hepatic encephalopathy
Recommendation ID NG52/2 Question Factors predicting outcomes for people with high-grade transformation of follicular lymphoma:- In people
Recommendation ID NG52/1 Question Baseline FDG-PET-CT imaging for people with diffuse large B-cell lymphoma stage II or above:- In people
Recommendation ID NG52/3 Question Radiotherapy in first-line treatment of diffuse large B-cell lymphoma:- In people presenting with diffuse
From £1 to £180: how NICE guidance helped us make smarter slide sheet choices
Learn how our evidence-based guidance helped a London NHS trust standardise procurement and generate operational efficiencies.
New treatment option recommended for recurrent or metastatic cervical cancer
A new treatment option is now available on the NHS for cervical cancer that has come back or spread to other parts of the body, following our final draft guidance published today.
First disease-modifying therapy for NHS use to delay the onset of type 1 diabetes recommended
A first-of-its-kind therapy that can delay the onset of type 1 diabetes for up to 3 years is to be made available on the NHS.
Learn how NICE's healthtech guidance is accelerating NHS adoption of a simple bowel cancer test, preventing 140,000 unnecessary urgent referrals a year while keeping cancer detection rates stable.
This guidance has been updated and replaced by NICE guideline NG47.
This guidance has been updated and replaced by NICE guideline NG151.
Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer (MTG72)
We have moved Medical technologies guidance 72 to become HealthTech guidance 642. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
GreenLight XPS for treating benign prostatic hyperplasia (MTG74)
We have moved Medical technologies guidance 74 to become HealthTech guidance 650. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved Medical technologies guidance 75 to become HealthTech guidance 651. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.